`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`STEADYMED LTD.,
`
`Petitioner,
`
`V.
`
`UNITED TI-IERAPEUTICS CORPORATION
`
`Patent Owner.
`
`Case lPR20 I 6—()00O6
`
`Patent No. 8,497,393 B2
`
`DECLARATION OF JAMES DOWDLE UNDER 37 C.F.R. § 42.63(B)
`
`I, James Dowdle declare:
`
`l.
`
`2.
`
`I am fluent in the Japanese and English languages.
`
`I am a Japanese translator from Japanese to English, and have been
`
`working as a translator since 2012.
`
`Wl{S'l"‘2(»‘)322-I94. I
`
`|PR2016-00006
`
`SteadyMed - Exhibit 1019 - Page 1
`
`IPR2016-00006
`SteadyMed - Exhibit 1019 - Page 1
`
`
`
`3.
`
`I received my Bachelor's Degree in Japanese from Brigham Young
`
`University in 2012. To receive my degree, I was required to do an entire thesis
`
`presentation in Japanese.
`
`I have also lived in Japan, where l worked as an intern
`
`teaching, English and studying Japanese literature and culture.
`
`4.
`
`I personally translated a Japanese Patent Application, which
`
`translation is now Ex. 1007, and my translation is a true and accurate translation of
`
`the Japanese Patent Application No. 56—l22328A (Kax-vakaini), Crystalline Amine
`
`Salt of Methanoprostacyclin Derivative, Manufacturing Method Thereof, and
`
`Purifying Method Thereof.
`
`5.
`
`I am confident that this translation is true and accurate, because it was
`
`checked by Mr. Boris Levine, who is an experienced Japanese—to—English
`
`translator.
`
`I hereby declare that all statements made herein are of my own personal
`
`knowledge; all statements made on information and belief are believed to be true;
`
`and all statements were made with the knowledge that willful false statements and
`
`the like so made are punishable by fine or imprisonment, or both, under Section
`
`United States Code.
` la. es Dbwdl
`
`Technical Language Services, lnc.
`April
`2:52
`, 2016
`
`\\'l{S’|"—2(>l)32Z~l9-I
`
`I
`
`L)
`
`|PR2016-00006
`
`SteadyMed - Exhibit 1019 - Page 2
`
`IPR2016-00006
`SteadyMed - Exhibit 1019 - Page 2
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the attached DECLARATION OF
`
`JAMES DOWDLE UNDER 37 C.F.R. § 42.63(B), was served via electronic mail
`
`to the following:
`
`Stephen B. Maebius
`George Quillin
`FOLEY & LARDNER LLP
`UT393-IPR@foley.com
`
`Shaun R. Snader
`UNITED THERAPEUTICS CORP.
`ssnader@unither.com
`
`Douglas Carsten
`Richard Torczon
`Robert Delafield
`WILSON, SONSINI, GOODRICH & ROSATI
`dcarsten@wsgr.com
`rtorczon@wsgr.com
`bdelafield@wsgr.com
`
`
`
`Respectfully submitted,
`
`
`/s Lisa A. Haile /
`Lisa A. Haile, J.D., Ph.D.
`Reg. No. 38,347
`DLA Piper LLP (US)
`
`
`
`Date: April 29, 2016
`
`
`/s Stuart E. Pollack /
`Stuart E. Pollack, J.D., Ph.D.
`Reg. No. 43,862
`DLA Piper LLP (US)
`
`
`
`WEST\269322494.1
`
`
`
`IPR2016-00006
`SteadyMed - Exhibit 1019 - Page 3